A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors - Trial NCT06337630
Access comprehensive clinical trial information for NCT06337630 through Pure Global AI's free database. This Phase 1 trial is sponsored by Institut Curie and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 92 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Institut Curie
Timeline & Enrollment
Phase 1
Jun 15, 2024
Feb 15, 2029
Primary Outcome
Dose escalation step : Dose limiting toxicities (DLTs),Expansion cohorts : Best tumor response,Expansion cohorts : Serious Adverse Events (SAEs),Expansion cohorts : Adverse Events (AEs)
Summary
Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor
 types.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06337630
Non-Device Trial